Depressive and negative symptoms in schizophrenia: different effects on clinical features

Rocca, Paola; Bellino, Silvio; Calvarese, P; Marchiaro, Livio; Patria, Luca; Rasetti, Roberta; Bogetto, Filippo

doi:10.1016/j.comppsych.2004.09.001

Cited by 72 publications

(80 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Future trials should further examine the association between the CDSS and patients’ psychopathology and should continue the discussion regarding the overlap between depressive and negative symptoms [36]. The stability and satisfying variance of the CDSS at both assessment time points suggest its advantage in the assessment of depressive symptoms in schizophrenia patients.…”

Section: Discussionmentioning

confidence: 99%

Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale

et al. 2012

View full text Add to dashboard Cite

Background: The aim of this study was to compare two measures of depression in patients with schizophrenia and schizophrenia spectrum disorder, including patients with delusional and schizoaffective disorder, to conclude implications for their application. Sampling and Methods: A total of 278 patients were assessed using the Calgary Depression Scale for Schizophrenia (CDSS) and the Hamilton Depression Rating Scale (HAMD-17). The Positive and Negative Syndrome Scale (PANSS) was also applied. At admission and discharge, a principal component analysis was performed with each depression scale. The two depression rating scales were furthermore compared using correlation and regression analyses. Results: Three factors were revealed for the CDSS and HAMD-17 factor component analysis. A very similar item loading was found for the CDSS at admission and discharge, whereas results of the loadings of the HAMD-17 items were less stable. The first two factors of the CDSS revealed correlations with positive, negative and general psychopathology. In contrast, multiple significant correlations were found for the HAMD-17 factors and the PANSS subscores. Multiple regression analyses demonstrated that the HAMD-17 accounted more for the positive and negative symptom domains than the CDSS. Conclusions: The present results suggest that compared to the HAMD-17, the CDSS is a more specific instrument to measure depressive symptoms in schizophrenia and schizophrenia spectrum disorder, especially in acutely ill patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In a study by Rocca et al, 23 male gender was associated with an increased severity of depressive symptoms. Our study also indicated that a slightly higher proportion of male patients than females suffered from depression.…”

Section: Discussionmentioning

confidence: 99%

Depression in Kraepelinian Schizophrenia

Naudé¹,

Sykes

Preez³

et al. 2009

S. Afr. J. Psych.

View full text Add to dashboard Cite

Objective. Depressive symptoms are prevalent, under- recognised and clinically important in patients suffering from schizophrenia. Depressive symptoms in schizophrenia patients are associated with distinct morbidity and mortality. The objective of this study was to investigate the prevalence of depressive symptoms in a subgroup of chronic schizophrenia, Kraepelinian schizophrenia, and the association with severity of illness. Kraepelinian schizophrenia is characterised by a chronic, unremitting, severe course of illness and severe deterioration of functioning in social, work and self-care domains. Method. The Calgary Depression Scale for Schizophrenia (CDSS) and the Clinical Global Impression Severity (CGI-S) scale were administered to 113 patients who fulfilled the criteria of Kraepelinian schizophrenia. Results. Sixty-eight males and 45 females participated in the study. Of this group, 17.7% scored 5 or more on the CDSS. The CGI-S scores indicated that almost half of the patients were moderately ill (i.e. a score of 4 on the CGI-S scale). Of the patients, 94 were receiving first-generation antipsychotic medication and 19 second- generation antipsychotic medication. Thirteen patients were also receiving antidepressant medication. Conclusion. The findings of this study are consistent with current reports in the literature that depressive symptoms are not common in Kraepelinian schizophrenia, even though patients are moderately to severely ill in both symptom and functional domains.

show abstract

“…It has been suggested that depression is more closely associated with interpersonal adjustment than severity of psychiatric symptoms (Rocca et al, 2005).…”

Section: Insert Table 4 Here Discussionmentioning

confidence: 99%

Acceptance and Commitment Therapy for depression following psychosis: An examination of clinically significant change

White

Gumley

McTaggart

et al. 2015

Journal of Contextual Behavioral Science

View full text Add to dashboard Cite

Depression following psychosis is common and can impact negatively on individuals' quality of life. This study conducted post-hoc analyses on 14 participants with psychosis from a larger randomised controlled trial who presented with clinically important levels of depression at baseline. Eight of the participants received Acceptance and Commitment Therapy (ACT), whilst the remaining six individuals received treatment as usual (TAU). The focus was on investigating clinically significant change in outcome measures between baseline and 3-months post-baseline in the participants. Participants completed measures assessing depression and anxiety (HADS), psychosis symptoms (PANSS) and psychological inflexibility (AAQ-II) between baseline and at 3-month post-baseline assessments. Odds ratio analysis indicated that participants receiving ACT, compared to TAU, were 15 times more likely to achieve clinically significant decreases in depression scores (Fisher's Exact Test p = 0.05). Differences between the ACT and TAU groups in clinically significant changes in anxiety, psychological inflexibility, positive symptoms, negative symptoms and general level of psychopathology were not statistically significant. The study provides tentative support for the use of ACT to treat depression emerging in the context of psychosis.

show abstract

Depressive and negative symptoms in schizophrenia: different effects on clinical features

Cited by 72 publications

References 76 publications

Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale

Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale

Depression in Kraepelinian Schizophrenia

Acceptance and Commitment Therapy for depression following psychosis: An examination of clinically significant change

Contact Info

Product

Resources

About